Understanding the glass-forming ability of active pharmaceutical ingredients for designing supersaturating dosage forms

Journal of Pharmaceutical Sciences

Volumn 101, Issue 9, 2012, Pages 3239-3248

  Kawakami, Kohsaku ^a   Usui, Toshinori ^b   Hattori, Mitsunari ^b  

^a NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

^b Mettler Toledo KK   (Japan)

Author keywords

Amorphous; Crystallization; Fragility; Glass transition; Glass forming ability; High speed DSC; Physical stability; Thermal analysis

Indexed keywords

CARBAMAZEPINE; FENOFIBRATE; HALOPERIDOL; IBUPROFEN; INDOMETACIN; ITRACONAZOLE; KETOCONAZOLE; NIFEDIPINE; PARACETAMOL; PROCAINE; TOLBUTAMIDE;

ARTICLE; COOLING; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DESIGN; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SCREENING; GLASS TRANSITION TEMPERATURE; IN VIVO STUDY; THERMODYNAMICS;

EID: 84864054858     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23166     Document Type: Article

References (29)

1. Kawakami K. 2009. Current status of amorphous formulation and other special dosage forms as formulations for early clinical phases. J Pharm Sci 98:2875-2885.
2. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. 2010. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J Pharm Sci 99:1254-1264.
3. Kawakami K. 2012. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs. Adv Drug Delivery Rev 64: 480-495.
4. Vandecruys R, Peeters J, Verreck G, Brewster, ME. 2007. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int J Pharm 342:168-175.
5. Brouwers J, Brewster ME, Augustijns P. 2009. Supersaturating drug delivery systems: The answer to solubility-limited oral bioavailability? J Pharm Sci 98:2549-2572.
6. Sollohub K, Cal K. 2010. Spray drying technique: II. Current applications in pharmaceutical technology. J Pharm Sci 99:587-597.
7. Breitenbach J. 2002. Melt extrusion: From process to drug delivery technology. Eur J Pharm Biopharm 54:107-117.
8. Bhugra C, Pikal MJ. 2008. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci 97:1329-1349.
9. Caron V, Bhugra C, Pikal MJ. 2010. Prediction of onset of crystallization in amorphous pharmaceutical systems: Phenobarbital, nifedipine/PVP, and phenobarbital/PVP. J Pharm Sci 99:3887-3900.
10. Tarjus G, Kivelson SA, Nussinov Z, Viot P. 2005. The frustration-based approach of supercooled liquids and the glass transition: A review and critical assessment. J Phys Condens Matter 17:R1143-R1182.
11. Tanaka H. 2005. Two-order parameter model of the liquid-glass transition. I. Relation between glass transition and crystallization. J Non-Cryst Solids 351:3371-3384.
12. Shintani H, Tanaka H. 2006. Frustration on the way to crystallization in glass. Nat Phys 2:200-206.
13. Baird JA, van Eerdenbrugh B, Taylor LS. 2010. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci 99:3787-3806.
14. Gu CH, Young Jr. V, Grant DJW. 2001. Polymorph screening: Influence of solvents on the rate of solvent-mediated polymorphic transformation. J Pharm Sci 90:1878-1890.
15. Kawakami K, Asami Y, Takenoshita I. 2010. Calorimetric investigation of solvent-mediated transformation of sulfamerazine polymorphism. J Pharm Sci 99:76-81
16. Kawakami K. 2007. Reversibility of enantiotropically-related polymorphic transformations from a practical viewpoint: Thermal analysis of kinetically reversible/irreversible polymorphic transformations. J Pharm Sci 96:982-989.
17. Kawakami K. 2010. Parallel thermal analysis technology using an infrared camera for high-throughput evaluation of active pharmaceutical ingredients: A case study of melting point determination. AAPS PharmSciTech 11:1020-1205.
18. g temperature region. J Phys Chem B 115:11375-11381.
19. Senkov ON. 2007. Correlation between fragility and glass-forming ability of metallic alloys. Phys Rev B 76:104202-1-104202-6.
20. Crowley KJ, Zografi G. 2001. The use of thermal methods for predicting glass-former fragility. Thermochim Acta 380:79-93.
21. Baird JA, Santiago-Quinonez D, Rinaldi C, Taylor LS. 2012. Role of viscosity in influencing the glass-forming ability of organic molecules from the undercooled melt state. Pharm Res 29:271-284.
22. Huang D, McKenna GB. 2001. New insights into the fragility dilemma in liquids. J Chem Phys 114:5621-5630.
23. Wang LM, Velikov V, Angell CA. 2002. Direct determination of kinetic fragility indices of glass-forming liquids by differential scanning calorimetry: Kinetic versus thermodynamic fragilities. J Chem Phys 117:10184-10192.
24. Kawakami K, Pikal MJ. 2005. Calorimetric investigation of the structural relaxation of amorphous materials: Evaluating validity of the methodologies. J Pharm Sci 94:948-965.
25. Yalkowsky SH, He Y. 2003. Handbook of aqueous solubility Data. Boca Raton, Florida: CRC Press, 2003.
26. Law D, Wang W, Schmitt EA, Qiu Y, Krill SL, Fort JJ. 2003. Properties of rapidly dissolving eutectic mixtures of poly(ethylene glycol) and fenofibrate: The eutectic microstructure. J Pharm Sci 92:505-515.
27. Peeters J, Neeskens P, Tollenaere J, Van Remoortere P, Brewster ME. 2002. Characterization of the interaction of 2-hydroxypropyl-β-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci 91:1414-1422.
28. 1H NMR relaxation times. J Pharm Sci 89:408-416.
29. Alonzo DE, Gao Y, Zhou D, Mo H, Zhang GGZ, Taylor LS. 2011. Dissolution and precipitation behavior of amorphous solid dispersions. J Pharm Sci 100:3316-3331.